Shinpoong Pharmaceutical (KRX: 019170)
Who is buying Shinpoong Pharmaceutical?
Between Sep 15, 2026 and Oct 16, 2026 (20 trading sessions), foreign investors net bought ₩3.8bn ($3M) of Shinpoong Pharmaceutical, the 76th largest foreign net purchase among 832 KOSPI stocks. Institutions net sold ₩0.2bn ($0M) and retail investors net sold ₩3.8bn ($3M) over the same window. Foreigners were net buyers on 16 of the 20 sessions.
Foreign investors hold 4.57% of Shinpoong Pharmaceutical's listed shares (KRX ownership data as of Oct 16, 2026), up from 4.22% twenty sessions earlier and 5.12% a year ago.
The stock closed at ₩9,600 on Oct 16, 2026: -4.67% over 20 sessions, -31.62% year-to-date, -26.88% over one year. The 52-week range is ₩6,310 – ₩15,900.
At ₩9,600 the stock trades at 55.81× trailing earnings (KRX, last completed fiscal year); no analyst consensus is available for a forward P/E.
View chart data as a table
| Date | Close | Foreign net | Institutions | Retail |
|---|---|---|---|---|
| 2026-10-16 | ₩9,600 | +₩2.3bn | ₩0.0bn | ₩-2.3bn |
| 2026-10-15 | ₩9,200 | +₩0.2bn | +₩0.0bn | ₩-0.2bn |
| 2026-10-14 | ₩9,470 | +₩0.8bn | +₩0.0bn | ₩-0.8bn |
| 2026-10-13 | ₩9,560 | +₩0.4bn | +₩0.0bn | ₩-0.4bn |
| 2026-10-12 | ₩9,300 | +₩0.1bn | +₩0.0bn | ₩-0.1bn |
| 2026-10-08 | ₩9,780 | ₩-4.6bn | +₩0.0bn | +₩4.5bn |
| 2026-10-07 | ₩11,010 | +₩0.2bn | ₩-0.2bn | ₩-0.0bn |
| 2026-10-06 | ₩9,670 | +₩0.8bn | +₩0.0bn | ₩-0.8bn |
| 2026-10-02 | ₩9,250 | ₩-0.2bn | ₩0.0bn | +₩0.3bn |
| 2026-10-01 | ₩9,380 | +₩1.3bn | ₩0.0bn | ₩-1.3bn |
| 2026-09-30 | ₩9,030 | +₩0.5bn | ₩0.0bn | ₩-0.5bn |
| 2026-09-29 | ₩8,980 | ₩-0.1bn | ₩0.0bn | +₩0.1bn |
| 2026-09-28 | ₩9,270 | +₩0.2bn | ₩0.0bn | ₩-0.2bn |
| 2026-09-23 | ₩9,250 | +₩0.5bn | ₩-0.0bn | ₩-0.5bn |
| 2026-09-22 | ₩9,270 | +₩0.2bn | ₩-0.0bn | ₩-0.2bn |
| 2026-09-21 | ₩9,350 | +₩0.4bn | +₩0.0bn | ₩-0.4bn |
| 2026-09-18 | ₩9,420 | +₩0.3bn | ₩-0.0bn | ₩-0.3bn |
| 2026-09-17 | ₩9,400 | +₩0.9bn | ₩0.0bn | ₩-0.9bn |
| 2026-09-16 | ₩9,200 | ₩-0.6bn | ₩-0.0bn | +₩0.6bn |
| 2026-09-15 | ₩9,970 | +₩0.1bn | +₩0.0bn | ₩-0.1bn |
| 2026-09-14 | ₩10,070 | ₩-0.1bn | +₩0.0bn | +₩0.1bn |
| 2026-09-11 | ₩10,020 | ₩-2.1bn | +₩0.0bn | +₩2.1bn |
| 2026-09-10 | ₩9,850 | +₩1.3bn | ₩-0.7bn | ₩-0.6bn |
| 2026-09-09 | ₩9,820 | ₩-0.3bn | +₩0.0bn | +₩0.3bn |
| 2026-09-08 | ₩9,940 | ₩-1.2bn | ₩0.0bn | +₩1.2bn |
| 2026-09-07 | ₩9,820 | +₩0.1bn | ₩-0.0bn | ₩-0.1bn |
| 2026-09-04 | ₩10,010 | ₩-0.1bn | +₩0.0bn | +₩0.1bn |
| 2026-09-03 | ₩10,100 | ₩-1.2bn | ₩-0.0bn | +₩0.5bn |
| 2026-09-02 | ₩10,380 | ₩-3.2bn | +₩0.2bn | +₩3.0bn |
| 2026-09-01 | ₩10,500 | +₩1.6bn | ₩-0.0bn | ₩-1.7bn |
| 2026-08-31 | ₩10,410 | ₩-1.4bn | ₩-0.9bn | +₩2.4bn |
| 2026-08-28 | ₩10,090 | ₩-1.0bn | ₩-0.0bn | +₩1.1bn |
| 2026-08-27 | ₩8,840 | ₩-0.6bn | ₩-0.0bn | +₩0.5bn |
| 2026-08-26 | ₩9,300 | ₩-0.7bn | ₩0.0bn | +₩0.8bn |
| 2026-08-25 | ₩9,230 | ₩-2.2bn | ₩-0.1bn | +₩2.2bn |
| 2026-08-24 | ₩10,550 | ₩-2.6bn | ₩-0.1bn | +₩3.6bn |
| 2026-08-21 | ₩8,120 | ₩-0.1bn | ₩-0.0bn | +₩0.1bn |
| 2026-08-20 | ₩8,400 | +₩0.1bn | +₩0.0bn | ₩-0.1bn |
| 2026-08-19 | ₩8,210 | +₩0.0bn | ₩-0.0bn | ₩-0.0bn |
| 2026-08-18 | ₩8,350 | ₩-0.3bn | ₩-0.0bn | +₩0.3bn |
| 2026-08-14 | ₩8,790 | +₩0.1bn | +₩0.0bn | ₩-0.1bn |
| 2026-08-13 | ₩8,750 | +₩0.1bn | +₩0.0bn | ₩-0.1bn |
| 2026-08-12 | ₩8,700 | ₩-0.3bn | +₩0.0bn | +₩0.3bn |
| 2026-08-11 | ₩8,870 | ₩-0.0bn | +₩0.0bn | ₩-0.0bn |
| 2026-08-10 | ₩8,890 | +₩0.2bn | +₩0.0bn | ₩-0.2bn |
| 2026-08-07 | ₩8,460 | +₩0.4bn | +₩0.0bn | ₩-0.4bn |
| 2026-08-06 | ₩8,020 | ₩-0.0bn | +₩0.0bn | ₩-0.0bn |
| 2026-08-05 | ₩8,140 | ₩-0.0bn | ₩0.0bn | +₩0.0bn |
| 2026-08-04 | ₩8,040 | +₩0.3bn | ₩0.0bn | ₩-0.3bn |
| 2026-08-03 | ₩7,770 | +₩0.1bn | ₩0.0bn | ₩-0.1bn |
| 2026-07-31 | ₩7,490 | +₩0.3bn | +₩0.0bn | ₩-0.3bn |
| 2026-07-30 | ₩7,210 | +₩0.3bn | ₩0.0bn | ₩-0.3bn |
| 2026-07-29 | ₩7,270 | +₩0.2bn | +₩0.0bn | ₩-0.2bn |
| 2026-07-28 | ₩7,630 | ₩-0.0bn | +₩0.0bn | ₩-0.0bn |
| 2026-07-27 | ₩7,830 | ₩-0.2bn | ₩0.0bn | +₩0.1bn |
| 2026-07-24 | ₩7,870 | +₩0.1bn | ₩-0.0bn | ₩-0.1bn |
| 2026-07-23 | ₩7,900 | +₩0.4bn | ₩0.0bn | ₩-0.4bn |
| 2026-07-22 | ₩7,610 | ₩-0.2bn | ₩0.0bn | +₩0.2bn |
| 2026-07-21 | ₩7,690 | ₩-0.1bn | ₩0.0bn | +₩0.1bn |
| 2026-07-20 | ₩7,720 | ₩-0.1bn | ₩0.0bn | +₩0.1bn |
| 2026-07-16 | ₩8,040 | +₩0.0bn | +₩0.0bn | ₩-0.0bn |
Investor flows summary
| Window | Foreign | (USD) | Institutions | Retail |
|---|---|---|---|---|
| 1 day | +₩2.3bn | +$2M | ₩0.0bn | ₩-2.3bn |
| 5 days | +₩3.9bn | +$3M | +₩0.1bn | ₩-3.9bn |
| 20 days | +₩3.8bn | +$3M | ₩-0.2bn | ₩-3.8bn |
Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.
Frequently asked questions
Are foreign investors buying Shinpoong Pharmaceutical stock?
Over the last 5 sessions foreign investors net bought ₩3.9bn ($3M) of Shinpoong Pharmaceutical; over 60 sessions they net sold ₩8.8bn ($7M); since Jan 1, 2026 they net sold ₩13.9bn ($10M). Over 20 sessions the stock is the 76th largest foreign net purchase among 832 KOSPI stocks.
How much of Shinpoong Pharmaceutical do foreign investors own?
Foreign investors own 4.57% of Shinpoong Pharmaceutical's shares as of Oct 16, 2026, versus 5.12% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.
Who is on the other side — institutions or retail investors?
Over 20 sessions institutions net sold ₩0.2bn ($0M) and retail investors net sold ₩3.8bn ($3M) of Shinpoong Pharmaceutical. Foreign buying is being met mainly by retail selling.
Is Shinpoong Pharmaceutical listed on KOSPI or KOSDAQ?
Shinpoong Pharmaceutical (신풍제약) trades on KOSPI under KRX code 019170 in the Biotech & Pharma group, with a market capitalization of ₩1T ($0.4B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.
Annual financials
| Fiscal year | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| 2023 | ₩200bn ($149M) | – | -₩47bn (-$35M) | -₩57bn (-$43M) |
| 2024 | ₩221bn ($164M) | +10.40% | -₩20bn (-$15M) | -₩15bn (-$11M) |
| 2025 | ₩235bn ($174M) | +6.10% | ₩14bn ($11M) | ₩8bn ($6M) |
Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1345.9/$) for reference only.